HIF1A and neoplasm: Thus, decreasing m6A is potentially implicated in tumor therapy by downregulating oncogene expression and upregulating tumor suppressor genes in various key pathways, including Wnt/β-catenin, proliferation/survival via direct mRNA regulation, and transcription factors such as HIF-1, CHX8, and SRF.